Erich Bam
Directeur des opérations chez ViRexx Medical Corp.
Postes actifs de Erich Bam
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
ViRexx Medical Corp.
 ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Directeur des opérations | 12/10/2007 | - |
Historique de carrière de Erich Bam
Formation de Erich Bam
| University of Stellenbosch | Undergraduate Degree |
| University of South Africa | Graduate Degree |
Statistiques
Internationale
| Afrique du Sud | 3 |
| Canada | 2 |
Opérationnelle
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
ViRexx Medical Corp.
ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |
